Table of Contents Author Guidelines Submit a Manuscript
Bone Marrow Research
Volume 2012, Article ID 897215, 11 pages
http://dx.doi.org/10.1155/2012/897215
Review Article

Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma

1Myeloma and Lymphoma Service, Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV 26506, USA
2Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
3Division of Hematology and Oncology, West Virginia University, P.O. Box 9162, 1 Medical Center Drive, Morgantown, WV 26506, USA

Received 30 July 2012; Revised 19 September 2012; Accepted 19 September 2012

Academic Editor: Joseph H. Antin

Copyright © 2012 Abraham S. Kanate et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Ayala and M. Tomblyn, “Hematopoietic cell transplantation for lymphomas,” Cancer Control, vol. 18, pp. 246–257, 2011. View at Google Scholar
  2. L. H. Sehn, T. S. Fenske, and G. G. Laport, “Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 18, pp. S82–S91, 2012. View at Google Scholar
  3. P. Solal-Celigny, P. Roy, P. Colombat et al., “Follicular lymphoma international prognostic index,” Blood, vol. 104, no. 5, pp. 1258–1265, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Buske, E. Hoster, M. Dreyling, J. Hasford, M. Unterhalt, and W. Hiddemann, “The follicular lymphoma international prognostic index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome,” Blood, vol. 108, no. 5, pp. 1504–1508, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. Czuczman, R. Weaver, B. Alkuzweny, J. Berlfein, and A. J. Grillo-López, “Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-Year follow-up,” Journal of Clinical Oncology, vol. 22, no. 23, pp. 4711–4716, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Hiddemann, M. Kneba, M. Dreyling et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group,” Blood, vol. 106, no. 12, pp. 3725–3732, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Marcus, K. Imrie, P. Solal-Celigny et al., “Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4579–4586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. L. Sorror, S. Giralt, B. M. Sandmaier et al., “Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences,” Blood, vol. 110, no. 13, pp. 4606–4613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Hamadani, M. Craig, F. T. Awan, and S. M. Devine, “How we approach patient evaluation for hematopoietic stem cell transplantation,” Bone Marrow Transplantation, vol. 45, no. 8, pp. 1259–1268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. R. Brown, Y. Feng, J. G. Gribben et al., “Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission,” Biology of Blood and Marrow Transplantation, vol. 13, no. 9, pp. 1057–1065, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Lenz, M. Dreyling, E. Schiegnitz et al., “Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group,” Blood, vol. 104, no. 9, pp. 2667–2674, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Sebban, N. Mounier, N. Brousse et al., “Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA),” Blood, vol. 108, no. 8, pp. 2540–2544, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Gyan, C. Foussard, P. Bertrand et al., “High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years,” Blood, vol. 113, no. 5, pp. 995–1001, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Ladetto, F. De Marco, F. Benedetti et al., “Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage,” Blood, vol. 111, no. 8, pp. 4004–4013, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Lenz, M. Dreyling, E. Schiegnitz et al., “Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group,” Journal of Clinical Oncology, vol. 22, no. 24, pp. 4926–4933, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Salles, N. Mounier, S. De Guibert et al., “Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study,” Blood, vol. 112, no. 13, pp. 4824–4831, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Ladetto, F. De Marco, F. Benedetti et al., “Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage,” Blood, vol. 111, no. 8, pp. 4004–4013, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Al Khabori, J. R. de Almeida, G. H. Guyatt et al., “Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis,” Journal of the National Cancer Institute, vol. 104, pp. 18–28, 2012. View at Google Scholar
  19. M. Schaaf, M. Reiser, P. Borchmann, A. Engert, and N. Skoetz, “High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults,” Cochrane Database of Systematic Reviews, vol. 1, Article ID CD007678, 2012. View at Google Scholar · View at Scopus
  20. F. Morschhauser, J. Radford, A. Van Hoof et al., “Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5156–5164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Salles, J. F. Seymour, F. Offner et al., “Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial,” The Lancet, vol. 377, no. 9759, pp. 42–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Kahl, F. Hong, M. E. Williams et al., “Results of eastern cooperative oncology group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma,” Blood, vol. 118, LBA-6, no. 21, 2011. View at Google Scholar
  23. A. K. Gopal, K. A. Guthrie, J. Rajendran et al., “90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma,” Blood, vol. 118, no. 4, pp. 1132–1139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Hamadani, D. M. Benson Jr., C. C. Hofmeister et al., “Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas,” Biology of Blood and Marrow Transplantation, vol. 15, no. 5, pp. 547–553, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. J. Bierman, J. M. Vose, J. R. Anderson, M. R. Bishop, A. Kessinger, and J. O. Armitage, “High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 15, no. 2, pp. 445–450, 1997. View at Google Scholar · View at Scopus
  26. T. M. Cao, S. J. Horning, R. S. Negrin et al., “High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience,” Biology of Blood and Marrow Transplantation, vol. 7, no. 5, pp. 294–301, 2001. View at Google Scholar · View at Scopus
  27. H. C. Schouten, W. Qian, S. Kvaloy et al., “High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial,” Journal of Clinical Oncology, vol. 21, no. 21, pp. 3918–3927, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Sebban, P. Brice, R. Delarue et al., “Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3614–3620, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Z. S. Rohatiner, L. Nadler, A. J. Davies et al., “Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up,” Journal of Clinical Oncology, vol. 25, no. 18, pp. 2554–2559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Montoto, C. Canals, A. Z. S. Rohatiner et al., “Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study,” Leukemia, vol. 21, no. 11, pp. 2324–2331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Van Besien, F. R. Loberiza, R. Bajorunaite et al., “Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma,” Blood, vol. 102, no. 10, pp. 3521–3529, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. A. S. Freedman, D. Neuberg, P. Mauch et al., “Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma,” Blood, vol. 94, no. 10, pp. 3325–3333, 1999. View at Google Scholar · View at Scopus
  33. C. Tarella, P. Corradini, M. Astolfi et al., “Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions,” Leukemia, vol. 13, no. 9, pp. 1456–1462, 1999. View at Google Scholar · View at Scopus
  34. C. Tarella, M. Zanni, M. Magni et al., “Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter gruppo italiano terapie innnovative nei linfomi survey,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3166–3175, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Arcaini, F. Montanari, E. P. Alessandrino et al., “Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma,” Annals of Oncology, vol. 19, no. 7, pp. 1331–1335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Crippa, L. Holmberg, R. A. Carter et al., “Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 8, no. 5, pp. 281–289, 2002. View at Google Scholar · View at Scopus
  37. L. K. Hicks, A. Woods, R. Buckstein et al., “Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma,” Bone Marrow Transplantation, vol. 43, no. 9, pp. 701–708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Pettengell, N. Schmitz, C. Gisselbrecht et al., “Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy,” Journal of Clinical Oncology, vol. 28, no. 15, p. 8005, 2010. View at Google Scholar
  39. M. Magni, M. Di Nicola, C. Carlo-Stella et al., “High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen,” Bone Marrow Transplantation, vol. 43, no. 6, pp. 509–511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. C. M. P. W. Mandigers, L. F. Verdonck, J. P. P. Meijerink, A. W. Dekker, A. V. M. B. Schattenberg, and J. M. M. Raemaekers, “Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation,” Bone Marrow Transplantation, vol. 32, no. 12, pp. 1159–1163, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Armand, H. T. Kim, V. T. Ho et al., “Allogeneic transplantation with reduced-intensity conditioning for hodgkin and non-hodgkin lymphoma: importance of histology for outcome,” Biology of Blood and Marrow Transplantation, vol. 14, no. 4, pp. 418–425, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. I. F. Khouri, “Allogeneic stem cell transplantation in follicular lymphoma,” Best Practice and Research, vol. 24, no. 2, pp. 271–277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. M. P. Escalón, R. E. Champlin, R. M. Saliba et al., “Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2419–2423, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Branson, R. Chopra, P. D. Kottaridis et al., “Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies,” Journal of Clinical Oncology, vol. 20, no. 19, pp. 4022–4031, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. A. J. Peniket, M. C. Ruiz de Elvira, G. Taghipour et al., “An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation,” Bone Marrow Transplantation, vol. 31, no. 8, pp. 667–678, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. I. Avivi, S. Montoto, C. Canals et al., “Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation,” British Journal of Haematology, vol. 147, no. 5, pp. 719–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Hari, J. Carreras, M. J. Zhang et al., “Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning,” Biology of Blood and Marrow Transplantation, vol. 14, no. 2, pp. 236–245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. I. F. Khouri, P. McLaughlin, R. M. Saliba et al., “Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab,” Blood, vol. 111, no. 12, pp. 5530–5536, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. K. J. Thomson, E. C. Morris, D. Milligan et al., “T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma,” Journal of Clinical Oncology, vol. 28, no. 23, pp. 3695–3700, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. J. L. Piñana, R. Martino, J. Gayoso et al., “Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials,” Haematologica, vol. 95, no. 7, pp. 1176–1182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Shea, J. Johnson, P. Westervelt et al., “Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901,” Biology of Blood and Marrow Transplantation, vol. 17, pp. 1395–1403, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. I. F. Khouri, R. M. Saliba, W. D. Erwin et al., “Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results,” Blood, vol. 119, pp. 6373–6378, 2012. View at Google Scholar
  53. M. R. Tomblyn, M. Ewell, C. Bredeson et al., “Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular Non-Hodgkin lymphoma beyond first complete response or first partial response,” Biology of Blood and Marrow Transplantation, vol. 17, no. 7, pp. 1051–1057, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Cohen, T. Kiss, S. Lachance et al., “Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity,” Biology of Blood and Marrow Transplantation, vol. 18, pp. 951–957, 2012. View at Google Scholar
  55. A. J. Al-Tourah, K. K. Gill, M. Chhanabhai et al., “Population-based analysis of incidence and outcome of transformed non-hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5165–5169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. J. W. Friedberg, D. Neuberg, J. G. Gribben et al., “Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies,” Biology of Blood and Marrow Transplantation, vol. 5, no. 4, pp. 262–268, 1999. View at Google Scholar · View at Scopus
  57. C. D. Williams, C. N. Harrison, T. A. Lister et al., “High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European bone marrow transplant registry,” Journal of Clinical Oncology, vol. 19, no. 3, pp. 727–735, 2001. View at Google Scholar · View at Scopus
  58. C. I. Chen, M. Crump, R. Tsang, A. Keith Stewart, and A. Keating, “Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma,” British Journal of Haematology, vol. 113, no. 1, pp. 202–208, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Hamadani, D. M. Benson, T. S. Lin, P. Porcu, K. A. Blum, and S. M. Devine, “High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma,” European Journal of Haematology, vol. 81, no. 6, pp. 425–431, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. M. B. Eide, G. F. Lauritzsen, G. Kvalheim et al., “High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study,” British Journal of Haematology, vol. 152, no. 5, pp. 600–610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. C. D. Williams, C. N. Harrison, T. A. Lister et al., “High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European bone marrow transplant registry,” Journal of Clinical Oncology, vol. 19, no. 3, pp. 727–735, 2001. View at Google Scholar · View at Scopus
  62. A. R. Rezvani, L. Norasetthada, T. Gooley et al., “Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience,” British Journal of Haematology, vol. 143, no. 3, pp. 395–403, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. N. Novitzky and V. Thomas, “Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies,” Biology of Blood and Marrow Transplantation, vol. 13, no. 1, pp. 107–115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. D. M. Oliansky, L. I. Gordon, J. King et al., “The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review,” Biology of Blood and Marrow Transplantation, vol. 16, no. 4, pp. 443–468, 2010. View at Publisher · View at Google Scholar · View at Scopus